143 related articles for article (PubMed ID: 33488971)
1. Solution Conformations Shed Light on PROTAC Cell Permeability.
Atilaw Y; Poongavanam V; Svensson Nilsson C; Nguyen D; Giese A; Meibom D; Erdelyi M; Kihlberg J
ACS Med Chem Lett; 2021 Jan; 12(1):107-114. PubMed ID: 33488971
[TBL] [Abstract][Full Text] [Related]
2. Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape.
Price E; Weinheimer M; Rivkin A; Jenkins G; Nijsen M; Cox PB; DeGoey D
J Med Chem; 2024 Apr; 67(7):5683-5698. PubMed ID: 38498697
[TBL] [Abstract][Full Text] [Related]
3. IMHB-Mediated Chameleonicity in Drug Design: A Focus on Structurally Related PROTACs.
Garcia Jimenez D; Rossi Sebastiano M; Vallaro M; Ermondi G; Caron G
J Med Chem; 2024 Jun; ():. PubMed ID: 38943610
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
Hanafi M; Chen X; Neamati N
J Med Chem; 2021 Feb; 64(3):1626-1648. PubMed ID: 33506674
[TBL] [Abstract][Full Text] [Related]
5. Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function.
Luo M; Spradlin JN; Boike L; Tong B; Brittain SM; McKenna JM; Tallarico JA; Schirle M; Maimone TJ; Nomura DK
Cell Chem Biol; 2021 Apr; 28(4):559-566.e15. PubMed ID: 33513350
[TBL] [Abstract][Full Text] [Related]
6. The rise of covalent proteolysis targeting chimeras.
Gabizon R; London N
Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy.
Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Chen J; Corr N; Dela Cruz-Chuh J; Del Rosario G; Fullerton A; Hartman SJ; Jiang F; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Lu Y; Mulvihill MM; Murray JM; O'Donohue A; Rowntree RK; Sawyer WS; Staben LR; Wai J; Wang J; Wei B; Wei W; Xu Z; Yao H; Yu SF; Zhang D; Zhang H; Zhang S; Zhao Y; Zhou H; Zhu X
J Med Chem; 2021 Mar; 64(5):2576-2607. PubMed ID: 33596073
[TBL] [Abstract][Full Text] [Related]
8. Mutant-selective degradation by BRAF-targeting PROTACs.
Alabi S; Jaime-Figueroa S; Yao Z; Gao Y; Hines J; Samarasinghe KTG; Vogt L; Rosen N; Crews CM
Nat Commun; 2021 Feb; 12(1):920. PubMed ID: 33568647
[TBL] [Abstract][Full Text] [Related]
9. PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery.
Ermondi G; Garcia-Jimenez D; Caron G
Molecules; 2021 Jan; 26(3):. PubMed ID: 33525371
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties.
Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Bhakta S; Blaquiere N; Chen J; Dela Cruz-Chuh J; Gascoigne KE; Hartman SJ; He M; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Liu L; Liu Q; Lu Y; Meng F; Mulvihill MM; O'Donohue A; Rowntree RK; Staben LR; Staben ST; Wai J; Wang J; Wei B; Wilson C; Xin J; Xu Z; Yao H; Zhang D; Zhang H; Zhou H; Zhu X
J Med Chem; 2021 Mar; 64(5):2534-2575. PubMed ID: 33596065
[TBL] [Abstract][Full Text] [Related]
11. Proteolytic Targeting Chimeras with Specificity for Plasma Membrane and Intracellular Estrogen Receptors.
Lu AS; Rouhimoghadam M; Arnatt CK; Filardo EJ; Salem AK
Mol Pharm; 2021 Mar; 18(3):1455-1469. PubMed ID: 33600191
[TBL] [Abstract][Full Text] [Related]
12. TRIP12 promotes small-molecule-induced degradation through K29/K48-branched ubiquitin chains.
Kaiho-Soma A; Akizuki Y; Igarashi K; Endo A; Shoda T; Kawase Y; Demizu Y; Naito M; Saeki Y; Tanaka K; Ohtake F
Mol Cell; 2021 Apr; 81(7):1411-1424.e7. PubMed ID: 33567268
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the binding affinity of E3 ubiquitin ligase ligands by cellular target engagement and in-cell ELISA assay.
Yang K; Zhou Y; Roberts BL; Nie X; Tang W
STAR Protoc; 2021 Mar; 2(1):100288. PubMed ID: 33532735
[TBL] [Abstract][Full Text] [Related]
14. Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta.
Bai N; Miller SA; Andrianov GV; Yates M; Kirubakaran P; Karanicolas J
J Chem Inf Model; 2021 Mar; 61(3):1368-1382. PubMed ID: 33625214
[TBL] [Abstract][Full Text] [Related]
15. Proteolysis-targeting chimera against BCL-X
Kolb R; De U; Khan S; Luo Y; Kim MC; Yu H; Wu C; Mo J; Zhang X; Zhang P; Zhang X; Borcherding N; Koppel D; Fu YX; Zheng SG; Avram D; Zheng G; Zhou D; Zhang W
Nat Commun; 2021 Feb; 12(1):1281. PubMed ID: 33627663
[TBL] [Abstract][Full Text] [Related]
16. PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance.
Giardina SF; Valdambrini E; Warren JD; Barany F
Curr Cancer Drug Targets; 2021; 21(4):306-325. PubMed ID: 33535953
[TBL] [Abstract][Full Text] [Related]
17. The Vital Role of Proteomics in Characterizing Novel Protein Degraders.
Zhang AX; Cassidy K; Dahl G; Moreau K; Pachl F; Zuhl AM
SLAS Discov; 2021 Apr; 26(4):518-523. PubMed ID: 33615886
[TBL] [Abstract][Full Text] [Related]
18. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses.
Ma Y; Frutos-Beltrán E; Kang D; Pannecouque C; De Clercq E; Menéndez-Arias L; Liu X; Zhan P
Chem Soc Rev; 2021 Apr; 50(7):4514-4540. PubMed ID: 33595031
[TBL] [Abstract][Full Text] [Related]
19. Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer.
Yokoo H; Shibata N; Naganuma M; Murakami Y; Fujii K; Ito T; Aritake K; Naito M; Demizu Y
ACS Med Chem Lett; 2021 Feb; 12(2):236-241. PubMed ID: 33603969
[TBL] [Abstract][Full Text] [Related]
20. CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.
Hansen JD; Correa M; Alexander M; Nagy M; Huang D; Sapienza J; Lu G; LeBrun LA; Cathers BE; Zhang W; Tang Y; Ammirante M; Narla RK; Piccotti JR; Pourdehnad M; Lopez-Girona A
J Med Chem; 2021 Feb; 64(4):1835-1843. PubMed ID: 33591756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
